Immune Pharmaceuticals Announces Corporate Restructuring – Yahoo Finance

NEW YORK, April 24, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced a major corporate restructuring with the objective of prioritizing and segregating its research and development efforts on a focused set…

Immune Pharma (IMNP) Announces Corporate Restructuring, CEO to Resign – StreetInsider.com

Get access to the best calls on Wall Street with StreetInsider.com’s Ratings Insider Elite. Get your Free Trial here. Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced a major corporate restructuring with the objective of prioritizing and segregating its research and development efforts on a focused set of products in inflammatory disease and dermatology and strengthening its…

Immune Pharmaceuticals Announces Corporate Restructuring – PR Newswire (press release)

A potential spin-off of Cytovia into a stand-alone company pursuing an independent path from Immune would provide several advantages: Allows current Immune investors to benefit from two distinct investment opportunities through proportional receipt of shares in Cytovia; Enables Cytovia to target new investors attracted to its specific oncology business profile and pursue distinct capital structures…

J&J “Making Good Progress” With Restructuring, Mulling “Various Options” For Diabetes Business – Med Device Online (press release)

By Jof EnriquezFollow me on Twitter @jofenriq Johnson & Johnson (J&J) says it is making good progress with ongoing restructuring of its medical device business, but the company still is considering various options for its diabetes unit, including potential partnerships or divestitures. The world’ largest healthcare products manufacturer reported that global medical device sales grew…